Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2025-12-25 @ 10:00 PM
Study NCT ID:
NCT05550558
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-09-28
First Post:
2022-09-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-11-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-11-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-11-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-20
First Submit QC Date:
None
Study First Post Date:
2022-09-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-26
Last Update Post Date:
2022-09-28
Last Update Post Date Type:
ACTUAL